声门鳞状细胞癌治疗中的放射疗法

Radiotherapy in the management of glottic squamous cell carcinoma.

作者信息

Mendenhall William M, Strojan Primož, Lee Anne W M, Rinaldo Alessandra, Eisbruch Avraham, Ng Wai Tong, Smee Robert, Ferlito Alfio

机构信息

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.

Department of Radiation Oncology, Institute of Oncology, Ljubljana, Slovenia.

出版信息

Head Neck. 2020 Dec;42(12):3558-3567. doi: 10.1002/hed.26419. Epub 2020 Sep 8.

DOI:10.1002/hed.26419

PMID:32896071

Abstract

INTRODUCTION

Our purpose is to review the role radiotherapy (RT) in the treatment of glottic squamous cell carcinoma (SCC).

METHODS

A concise review of the pertinent literature.

RESULTS

RT cure rates are Tis- T1N0, 90% to 95%; T2N0, 70% to 80%; low-volume T3-T4a, 65% to 70%. Concomitant cisplatin is given for T3-T4a SCCs. Severe complications occur in 1% to 2% for Tis-T2N0 and 10% for T3-T4a SCCs. Patients with high-volume T3-T4 SCCs undergo total laryngectomy, neck dissection, and postoperative RT. Those with positive margins and/or extranodal extension receive concomitant cisplatin. The likelihood of local-regional control at 5 years is 85% to 90%. Severe complications occur in 5% to 10%.

CONCLUSIONS

RT is a good treatment option for patients with Tis-T2N0 and low-volume T3-T4a glottic SCCs. Patients with higher volume T3-T4 cancers are best treated with surgery and postoperative RT.

摘要

引言

我们的目的是回顾放射治疗（RT）在声门鳞状细胞癌（SCC）治疗中的作用。

方法

对相关文献进行简要回顾。

结果

Tis - T1N0期的RT治愈率为90%至95%；T2N0期为70%至80%；低体积T3 - T4a期为65%至70%。T3 - T4a期SCC给予顺铂同步治疗。Tis - T2N0期严重并发症发生率为1%至2%，T3 - T4a期为10%。高体积T3 - T4期SCC患者接受全喉切除术、颈部清扫术及术后RT。切缘阳性和/或有结外侵犯的患者接受顺铂同步治疗。5年局部区域控制率为85%至90%。严重并发症发生率为5%至10%。